Health Catalyst Inc. (NASDAQ:HCAT) shares fell 24.68% in Thursday’s overnight session after the company forecast a sharp sequential revenue decline for the third quarter despite topping its own second-quarter guidance.
The stock closed Thursday’s regular session down 3.35% at $2.31 before falling another 24.68% to $1.74 in overnight trading.
Health Catalyst is a healthcare intelligence company that provides data and analytics solutions to health systems.
Guidance Overshadows Second-Quarter Results
For the quarter ended June 30, 2026, Health Catalyst reported revenue of $70.5 million, down 13% year over year. Gross profit declined 8% to $27.9 million, while adjusted EBITDA increased 6% to $9.9 million. The company reported a net loss of $40.5 million, compared with a net loss of $41 million in the prior-year period.
CEO Ben Albert said the company exceeded the high end of its revenue guidance and completed the divestiture of Vitalware, using the proceeds to fully repay its credit facility debt, strengthening its balance sheet.
For the third quarter, Health Catalyst expects revenue of $55 million to $56 million and adjusted EBITDA of break-even to $0.5 million. For the full year, the company expects revenue of $246 million to $249 million and adjusted EBITDA of $18 million to $18.5 million.
Trading Metrics
Health Catalyst has a market capitalization of approximately $170.7 million, with a 52-week high of $3.88 and a 52-week low of $0.96.
Over the past 12 months, HCAT shares are down 39.53%.
Benzinga Edge Stock Rankings show positive price trends across the short-, medium- and long-term time frames.
Disclaimer: This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock
Recent Comments